- President Donald Trump issued an executive order on April 18, 2026, aimed at accelerating the review process for certain psychedelic drugs to treat serious mental illnesses. This move seeks to ease restrictions and spur research into these substances.
- The order specifically targets drugs like ibogaine, which has shown potential in clinical studies for conditions such as severe depression and post-traumatic stress disorder. According to Reuters and Guardian staff, military veteran groups have highlighted ibogaine's potential to treat PTSD.
- The executive order directs the FDA to prioritize these drugs and establish pathways for eligible patients to access them under the Right to Try Act. This includes providing Commissioner's National Priority Vouchers for appropriate psychedelic drugs with Breakthrough Therapy designations.
- As reported by Bloomberg Law, Trump stated, "Today's order will ensure that people suffering from debilitating symptoms might finally have a chance to reclaim their lives and lead a happier life". The administration is taking steps to ease restrictions and spur research on using these drugs for medical purposes.
- The White House stated that the policy aims to "accelerate innovative research models and appropriate drug approvals to increase access to psychedelic drugs that could save lives and reverse the crisis of serious mental illness in America". The order also calls for $50 million in federal research into ibogaine.
- The order also directs the FDA to support new clinical trials for ibogaine, psilocybin, and other serotonin receptor drugs, and to swiftly approve those deemed safe and effective, as noted by The Washington Post. This initiative is seen by some as a turning point in the federal "war on drugs".
Trump Accelerates Psychedelic Drug Review
President Donald Trump issued an executive order on April 18, 2026, to fast-track the review and research of psychedelic drugs like ibogaine for serious mental illnesses such as PTSD and severe depression. This landmark directive aims to ease restrictions, prioritize FDA approval, allocate $50 million for ibogaine research, and establish patient access pathways, potentially marking a significant shift in federal drug policy.
Reporting Sources
6
Report an issue with this article
Please sign in to report issues with this article.
Live discussion about this article
Comments
Comments are disabled for this article.
